Fulcrum Therapeutics Inc
NASDAQ:FULC
Fulcrum Therapeutics Inc
Cash from Operating Activities
Fulcrum Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
Cash from Operating Activities
-$91m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is Fulcrum Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-91m
USD
Based on the financial report for Dec 31, 2023, Fulcrum Therapeutics Inc's Cash from Operating Activities amounts to -91m USD.
What is Fulcrum Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-32%
Over the last year, the Cash from Operating Activities growth was 6%. The average annual Cash from Operating Activities growth rates for Fulcrum Therapeutics Inc have been -19% over the past three years , -32% over the past five years .